Articles published by Delve Bio, Inc.

New Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/Encephalitis

Today 7:33 EDT

From Delve Bio, Inc.

Via Business Wire

New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing

June 22, 2025

From Delve Bio, Inc.

Via Business Wire

New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test

May 07, 2025

From Delve Bio, Inc.

Via Business Wire

Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting

April 07, 2025

From Delve Bio, Inc.

Via Business Wire

Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect

December 04, 2024

From Delve Bio, Inc.

Via Business Wire

Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections

November 21, 2024

From Delve Bio, Inc.

Via Business Wire

Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections

November 12, 2024

From Delve Bio, Inc.

Via Business Wire

Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections

June 17, 2024

From Delve Bio, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.